CLINICAL AND IMMUNOLOGICAL EFFICACY OF THE TREATMENT OF I AND II GENERATION PATIENTS WITH BRONCHIAL ASTHMA AFFECTED BY IONIZING RADIATION

This article describes the research of clinical and immunological efficacy of Wobenzym during the complex treatment of I, II generation patients with bronchial asthma affected by ionizing radiation. The randomized survey of 56 patients (30 males, 20 females) with moderately severe bronchial asthma in the age from 34 to 55 years old is conducted. The radiation route of patients is taking into account. Wobenzym is prescribed 5 pills three times a day (30-40 minutes before meal) during 12 days. The comparison group includes 28 patients, accepting basic ethiopathogenetic treat-ment. Patients with bronchial asthma get complex basic treatment. The control healthy group includes 30 persons. Immunity of patients with bronchial asthma is evaluated according to the magnification of CD3, CD4, and CD8 in peripheral blood, using homogeneous antibodies. Wobenzym efficacy evaluation is conducted on the basis of clinical criteria (durability of basic clinical symptoms during treatment) and dynamics of immunological factors. The data received was processed in the SPSS statistical program. The research has shown that Wobenzym usage during the complex treatment of I, II generation patients with bronchial asthma affected by ionizing radiation has improved the therapeutic effect. The research has shown that Wobenzym improves clinical and immunological effects (increase in CD3, CD4, decrease of imbalance CD4 / CD8, circulating immune complex recovery) of I, II generation patients with bronchial asthma affected by ionizing radiation.